Also trades as: TATVA.NS (NSE) · $vol 2M
TATVA.BO BSE
Tatva Chintan Pharma Chem Limited
1W: +0.9%
1M: +9.3%
3M: +40.1%
YTD: +46.0%
1Y: +63.7%
3Y: +4.9%
₹1,739.20 ($18.06)
-42.65 (-2.39%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$5.1B
+32.2% ▲
5Y CAGR: +11.0%
Gross Profit
$1.8B
+192.9% ▲
5Y CAGR: +4.9%
Operating Income
$563M
+521.7% ▲
5Y CAGR: -13.4%
Net Income
$421M
+636.1% ▲
5Y CAGR: -4.3%
EPS (Diluted)
$17.98
+636.9% ▲
5Y CAGR: -7.1%
EBITDA
$967M
+210.4% ▲
5Y CAGR: +7.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.2B | $3.9B | $3.8B | $5.1B |
| YoY Growth | +44.4% | -2.3% | -7.1% | -2.7% | +32.2% |
| Cost of Revenue | $2.0B | $2.3B | $1.8B | $2.0B | $3.2B |
| Gross Profit | $2.3B | $1.9B | $2.1B | $1.8B | $1.8B |
| Gross Margin | 53.5% | 45.1% | 53.5% | 48.0% | 35.9% |
| R&D Expenses | $37M | $60M | $79M | $84M | $0 |
| SG&A Expenses | $374M | $338M | $563M | $529M | $1.3B |
| Operating Expenses | $357M | $491M | $642M | $529M | $1.3B |
| Operating Income | $2.0B | $1.4B | $1.5B | $91M | $563M |
| Operating Margin | 45.3% | 33.5% | 37.2% | 2.4% | 11.1% |
| Interest Expense | $47M | $84M | $65M | $13M | $29M |
| Income Before Tax | $1.0B | $446M | $436M | $76M | $570M |
| Tax Expense | $82M | -$9M | $132M | $19M | $150M |
| Net Income | $959M | $455M | $304M | $57M | $421M |
| Net Margin | 22.1% | 10.7% | 7.7% | 1.5% | 8.3% |
| EPS (Diluted) | $44.59 | $20.52 | $13.26 | $2.44 | $17.98 |
| EBITDA | $1.1B | $676M | $689M | $342M | $967M |
| Shares Outstanding | 21M | 22M | 23M | 23M | 23M |